Home>Topics>Authors>Brian Laegeler

Brian Laegeler

  1. All
  2. Commentary
  3. Headlines
  1. Stockton is Bankrupt: Now What?

    Headlines

    Thu, 11 Apr 2013

    Tele Norte Leste Analyst Report: Vivo Participacoes Big Pharma Playing Rough with Generic Drugmakers As analyst Brian Laegeler wrote in his recent analysis of generic drug-maker Teva Pharmaceuticals TEVA, big pharma is taking a novel new

  2. A Quintet of Bargain Stocks

    Commentary

    Mon, 7 May 2007

    to our fair value estimate. At these prices, there should be enough value to go around for all parties involved. Brian Laegeler Angiotech Pharmaceuticals Highlights Pipeline (Maintaining) Angiotech Pharmaceuticals ANPI reported decent first-quarter

  3. Eight New Stocks on Sale

    Commentary

    Mon, 30 Apr 2007

    manufacturing cost advantage has dissipated with the appreciation of the Canadian dollar. While Morningstar analyst Brian Laegeler believes the business could be worth as much as $20 per share to a large competitor, the family controls almost

  4. Biogen Idec-Elan MS Drug Is Back

    Commentary

    Tue, 6 Jun 2006

    Serono SRA, Biogen's competitor in the multiple sclerosis market. While Tysabri may lure some patients away from Serono's Rebif, restrictive FDA safety guidelines reduce Tysabri's threat. Brian Laegeler contributed to this note.

Content Partners